Early Institutional Experience with One-Piece ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Early Institutional Experience with One-Piece Bifurcated-Fenestrated Stentgraft in the Treatment of Abdominal Aortic Aneurysms
Author(s) :
Mesnard, Thomas [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Pruvot, Louis [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Patterson, Benjamin Oliver [Auteur]
University Hospital Southampton NHS Foundation Trust
De Preville, Agathe [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Azzaoui, Richard [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Sobocinski, Jonathan [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008

Advanced Drug Delivery Systems (ADDS) - U1008
Pruvot, Louis [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Patterson, Benjamin Oliver [Auteur]
University Hospital Southampton NHS Foundation Trust
De Preville, Agathe [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Azzaoui, Richard [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Sobocinski, Jonathan [Auteur]

Advanced Drug Delivery Systems (ADDS) - U1008
Journal title :
Journal of endovascular therapy
Abbreviated title :
J. Endovascular Ther.
Volume number :
-
Pages :
-
Publisher :
SAGE Journal
Publication date :
2022-09-25
ISSN :
1526-6028
Keyword(s) :
bifurcated FEVAR
proximal endoleak
aortic endografts
proximal endoleak
aortic endografts
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Purpose:
To review the early experience of the use of a bifurcated-fenestrated endograft (Bif-FEVAR) to treat abdominal aortic aneurysms (AAA) in a high-volume aortic center.
Methods:
A retrospective single-center ...
Show more >Purpose: To review the early experience of the use of a bifurcated-fenestrated endograft (Bif-FEVAR) to treat abdominal aortic aneurysms (AAA) in a high-volume aortic center. Methods: A retrospective single-center analysis was conducted between March 2019 and April 2021 including consecutive patients that underwent Bif-FEVAR. Only patients without a proper infrarenal neck and a distance <70 mm between the lowest target artery and the native or prosthetic aortic bifurcation were considered. All Bif-FEVAR custom-made devices were manufactured by Cook Medical (Inc., Bloomington, Indiana). Demographics, anatomical features, technical success, major adverse events, 30-day mortality, and survival according to Kaplan–Meier were analyzed according to Society for Vascular Surgery standards. Results: Overall, 10 patients (100% male with median age 78) were included. The median preoperative maximal aneurysm diameter was 68 mm [51–84]. Eight patients were treated for a proximal type I endoleak after endovascular aneurysm repair. A total of 36 fenestrations were planned. The median operative time was 144 min [127–168], with a median fluoro time of 40.5 min [34–54] and a median dose area product of 73 Gy cm2 [61–89]. Technical success rate was 100%. No patients experienced a major postoperative adverse event. Median follow-up time was 8 months [6–13]. Conclusion: Bif-FEVAR is technically feasible when there is a short distance below the lowest target artery and the aortic bifurcation, with favorable short-term results. Clinical Impact This study assessed the use of an innovative one-piece bifurcated fenestrated stent-graft as a primary procedure or in the treatment of proximal endoleak after standard infrarenal EVAR. We demonstrated these custom-made devices can be used safely with favorable short-term results. One-piece bifurcated fenestrated stent-grafts extend the indications of FEVAR for patients with an unusually short distance between the lowest renal artery and the aorto-iliac bifurcation or the diverter flow of a preexisting bifurcated infrarenal stent-graft.Show less >
Show more >Purpose: To review the early experience of the use of a bifurcated-fenestrated endograft (Bif-FEVAR) to treat abdominal aortic aneurysms (AAA) in a high-volume aortic center. Methods: A retrospective single-center analysis was conducted between March 2019 and April 2021 including consecutive patients that underwent Bif-FEVAR. Only patients without a proper infrarenal neck and a distance <70 mm between the lowest target artery and the native or prosthetic aortic bifurcation were considered. All Bif-FEVAR custom-made devices were manufactured by Cook Medical (Inc., Bloomington, Indiana). Demographics, anatomical features, technical success, major adverse events, 30-day mortality, and survival according to Kaplan–Meier were analyzed according to Society for Vascular Surgery standards. Results: Overall, 10 patients (100% male with median age 78) were included. The median preoperative maximal aneurysm diameter was 68 mm [51–84]. Eight patients were treated for a proximal type I endoleak after endovascular aneurysm repair. A total of 36 fenestrations were planned. The median operative time was 144 min [127–168], with a median fluoro time of 40.5 min [34–54] and a median dose area product of 73 Gy cm2 [61–89]. Technical success rate was 100%. No patients experienced a major postoperative adverse event. Median follow-up time was 8 months [6–13]. Conclusion: Bif-FEVAR is technically feasible when there is a short distance below the lowest target artery and the aortic bifurcation, with favorable short-term results. Clinical Impact This study assessed the use of an innovative one-piece bifurcated fenestrated stent-graft as a primary procedure or in the treatment of proximal endoleak after standard infrarenal EVAR. We demonstrated these custom-made devices can be used safely with favorable short-term results. One-piece bifurcated fenestrated stent-grafts extend the indications of FEVAR for patients with an unusually short distance between the lowest renal artery and the aorto-iliac bifurcation or the diverter flow of a preexisting bifurcated infrarenal stent-graft.Show less >
Language :
Anglais
Audience :
Internationale
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Submission date :
2023-02-28T00:55:29Z
2023-03-08T07:09:37Z
2023-03-08T07:09:37Z